Moreau P, Jacotot B, Tillement J P
J Pharm Pharmacol. 1987 Jan;39(1):35-8. doi: 10.1111/j.2042-7158.1987.tb07158.x.
Moroxybrate, a drug obtained by the reaction of clofibric acid with moroxydine, a biguanide with practically no effect on carbohydrate metabolism, has been examined for its effects on blood lipids, fibrinogen, in-vitro platelet aggregation, and also on experimental atherosclerotic lesions obtained by feeding the rabbits a diet containing 1% cholesterol. At the same dose, moroxybrate has an effect at least equal to those of clofibrate and moroxydine alone, on the lipidic parameters and haemostasis in rat and rabbit. The combination of these actions together with an effect on the prevention of experimental atherosclerosis lesions in the rabbit suggests moroxybrate should be examined for its effects in ischaemic cardiovascular disease.
吗多明，一种由氯贝酸与吗啉胍反应制得的药物，吗啉胍对碳水化合物代谢几乎没有影响，已对其在血脂、纤维蛋白原、体外血小板聚集方面的作用进行了研究，还研究了其对通过给兔子喂食含1%胆固醇的饮食所形成的实验性动脉粥样硬化病变的影响。在相同剂量下，吗多明对大鼠和兔子的脂质参数及止血作用至少与单独使用氯贝丁酯和吗啉胍的效果相当。这些作用的组合以及对兔子实验性动脉粥样硬化病变预防的效果表明，应研究吗多明在缺血性心血管疾病中的作用。
